BACKGROUND: The objective of this study was to investigate the prognostic value of the pretreatment circulating neutrophil count (CNC), circulating monocyte count (CMC), and circulating lymphocyte count (CLC) in human papillomavirus (HPV)-related (HPV+) and HPV-unrelated (HPV-) oropharyngeal cancer (OPC). METHODS: All p16-confirmed HPV+ and HPV- OPC cases treated with chemoradiotherapy from 2000 to 2010 were included. Overall survival (OS) and recurrence-free survival (RFS) were compared for high and low CNCs, CMCs, and CLCs (dichotomized by median values). A multivariate analysis (MVA) confirmed their prognostic value in HPV+ and HPV- tumors, respectively. RESULTS: Five hundred ten HPV+ OPC cases and 192 HPV- OPC cases were included. The HPV+ cohort had lower CNC and CMC values but a CLC similar to that of the HPV- patients (P < .01). The median follow-up was 4.8 years. In the HPV+ cohort, a high CNC or CMC correlated with reduced OS and RFS in comparison with a low CNC or CMC (P < .01 for all), but no difference was evident in OS (P = .30) or RFS (P = .10) with the CLC. MVA confirmed that a higher CNC or CMC independently predicted lower OS (hazard ratio [HR] for CNC, 1.14, P < .01; HR for CMC, 2.95, P < .01) and lower RFS (HR for CNC, 1.11, P < .01; HR for CMC, 3.39, P < .01), whereas a higher CLC was associated with higher RFS (HR, 0.66, P = .03) and marginally higher OS (HR, 0.80, P = .08). In the HPV- cohort, CNC, CMC, and CLC were not predictive of OS (P = .16, P = .86, and P = .14) or RFS (P = .61, P = .59, and P = .62). CONCLUSIONS: This relatively large cohort study demonstrates that a high CNC and a high CMC independently predict inferior OS and RFS, whereas a high CLC predicts better RFS and marginally better OS in HPV+ OPC patients. This association was not apparent in HPV- patients.
BACKGROUND: The objective of this study was to investigate the prognostic value of the pretreatment circulating neutrophil count (CNC), circulating monocyte count (CMC), and circulating lymphocyte count (CLC) in human papillomavirus (HPV)-related (HPV+) and HPV-unrelated (HPV-) oropharyngeal cancer (OPC). METHODS: All p16-confirmed HPV+ and HPV- OPC cases treated with chemoradiotherapy from 2000 to 2010 were included. Overall survival (OS) and recurrence-free survival (RFS) were compared for high and low CNCs, CMCs, and CLCs (dichotomized by median values). A multivariate analysis (MVA) confirmed their prognostic value in HPV+ and HPV- tumors, respectively. RESULTS: Five hundred ten HPV+ OPC cases and 192 HPV- OPC cases were included. The HPV+ cohort had lower CNC and CMC values but a CLC similar to that of the HPV- patients (P < .01). The median follow-up was 4.8 years. In the HPV+ cohort, a high CNC or CMC correlated with reduced OS and RFS in comparison with a low CNC or CMC (P < .01 for all), but no difference was evident in OS (P = .30) or RFS (P = .10) with the CLC. MVA confirmed that a higher CNC or CMC independently predicted lower OS (hazard ratio [HR] for CNC, 1.14, P < .01; HR for CMC, 2.95, P < .01) and lower RFS (HR for CNC, 1.11, P < .01; HR for CMC, 3.39, P < .01), whereas a higher CLC was associated with higher RFS (HR, 0.66, P = .03) and marginally higher OS (HR, 0.80, P = .08). In the HPV- cohort, CNC, CMC, and CLC were not predictive of OS (P = .16, P = .86, and P = .14) or RFS (P = .61, P = .59, and P = .62). CONCLUSIONS: This relatively large cohort study demonstrates that a high CNC and a high CMC independently predict inferior OS and RFS, whereas a high CLC predicts better RFS and marginally better OS in HPV+ OPC patients. This association was not apparent in HPV- patients.
Authors: Martin Grimm; Johan Rieth; Sebastian Hoefert; Michael Krimmel; Sven Rieth; Peter Teriete; Susanne Kluba; Thorsten Biegner; Adelheid Munz; Siegmar Reinert Journal: Eur Arch Otorhinolaryngol Date: 2016-02-29 Impact factor: 2.503
Authors: M Giuliani; L R Sampson; O Wong; J Gay; L W Le; B C J Cho; A Brade; A Sun; A Bezjak; A J Hope Journal: Curr Oncol Date: 2016-08-12 Impact factor: 3.677
Authors: Cristina Valero; Daniella K Zanoni; Marlena R McGill; Ian Ganly; Luc G T Morris; Miquel Quer; Jatin P Shah; Richard J Wong; Xavier León; Snehal G Patel Journal: Cancer Date: 2019-12-06 Impact factor: 6.860
Authors: Sara Shoultz-Henley; Adam S Garden; Abdallah S R Mohamed; Tommy Sheu; Michael H Kroll; David I Rosenthal; G Brandon Gunn; Amos J Hayes; Chloe French; Hillary Eichelberger; Jayashree Kalpathy-Cramer; Blaine D Smith; Jack Phan; Zeina Ayoub; Stephen Y Lai; Brian Pham; Merrill Kies; Kathryn A Gold; Erich Sturgis; Clifton D Fuller Journal: Int J Cancer Date: 2015-10-09 Impact factor: 7.396
Authors: Camilla Engblom; Christina Pfirschke; Rapolas Zilionis; Janaina Da Silva Martins; Stijn A Bos; Gabriel Courties; Steffen Rickelt; Nicolas Severe; Ninib Baryawno; Julien Faget; Virginia Savova; David Zemmour; Jaclyn Kline; Marie Siwicki; Christopher Garris; Ferdinando Pucci; Hsin-Wei Liao; Yi-Jang Lin; Andita Newton; Omar K Yaghi; Yoshiko Iwamoto; Benoit Tricot; Gregory R Wojtkiewicz; Matthias Nahrendorf; Virna Cortez-Retamozo; Etienne Meylan; Richard O Hynes; Marie Demay; Allon Klein; Miriam A Bredella; David T Scadden; Ralph Weissleder; Mikael J Pittet Journal: Science Date: 2017-12-01 Impact factor: 47.728
Authors: Srikant Ambatipudi; Ryan Langdon; Rebecca C Richmond; Matthew Suderman; Devin C Koestler; Karl T Kelsey; Nabila Kazmi; Christopher Penfold; Karen M Ho; Wendy McArdle; Susan M Ring; Miranda Pring; Tim Waterboer; Michael Pawlita; Tom R Gaunt; George Davey Smith; Steve Thomas; Andy R Ness; Caroline L Relton Journal: Oral Oncol Date: 2018-09-05 Impact factor: 5.337
Authors: Alexander J Lin; Margery Gang; Yuan James Rao; Jian Campian; Mackenzie Daly; Hiram Gay; Peter Oppelt; Ryan S Jackson; Jason Rich; Randal Paniello; Jose Zevallos; Dennis Hallahan; Douglas Adkins; Wade Thorstad Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-05-01 Impact factor: 6.223